Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Adaptimmune Therapeutics PLC | Chief Business & Strgy Officer | Option to purchase Ordinary Shares | 565K | Jan 15, 2024 | Direct | ||
Trillium Therapeutics Inc. | Director | Deferred Share Unit | 0 | Nov 17, 2021 | Direct | ||
Trillium Therapeutics Inc. | Director | Stock Option (Right to Buy) | 0 | Nov 17, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ADAP | Adaptimmune Therapeutics PLC | Jan 15, 2024 | 2 | $0 | 4 | Jan 17, 2024 | Chief Business & Strgy Officer |
ADAP | Adaptimmune Therapeutics PLC | Jan 17, 2023 | 3 | $0 | 4 | Jan 17, 2023 | Chief Business & Strgy Officer |
ADAP | Adaptimmune Therapeutics PLC | Jan 12, 2022 | 2 | $0 | 4 | Jan 13, 2022 | Chief Business Officer |
TRIL | Trillium Therapeutics Inc. | Nov 17, 2021 | 2 | $0 | 4 | Nov 19, 2021 | Director |